<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02548325</url>
  </required_header>
  <id_info>
    <org_study_id>CorporacionPT</org_study_id>
    <nct_id>NCT02548325</nct_id>
  </id_info>
  <brief_title>Prevalence of Hepatitis B in Vallés Occidental. Observational Multicentric Study</brief_title>
  <official_title>Prevalence of Hepatitis B in Vallés Occidental. Observational Multicentric Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corporacion Parc Tauli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Mutua de Terrassa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Consorci Sanitari de Terrassa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Corporacion Parc Tauli</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the prevalence of hepatitis B in Vallés Occidental.
      Also, describe the stage of the disease, and whether if they are under medical treatment or
      not.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hepatitis B virus ( HBV ) is a global health problem . It is estimated that in the world
      there are about 350-400 million carriers of HBV surface antigen ( HBsAg ) 1 .

      The prevalence in Spain is estimated at a 2-7 % and is considered a second intermediate
      prevalence.

      For over 20 years, has carried out a program of primary prevention through universal
      vaccination against hepatitis B including it in the childhood vaccination schedule and has
      already been observed that in some estudi3 the prevalence has declined . For this reason , we
      want to evaluate what is the currently prevalence in our area of influence. There aren't
      recent studies to assess what is the current status of these patients ( how many , what risk
      factors which needs of treatment and with answer ...)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2014</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">May 31, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>prevalence hepatitis B</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>stage of the disease and if they are in treatment or not</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">1001</enrollment>
  <condition>Hepatitis B</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Not apply</intervention_name>
    <description>None. Just registration epidemiology dates</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The are Included consecutively for one year ( 1 June 2014 to 31 May 2015 ) all patients who
        are in the inclusion criteria
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with HBsAg + visited in Digestive/Hepatology outpatient visits and Hepatology
             of the participating hospitals

        Exclusion Criteria:

          -  Patients &lt; 18 aged

          -  Duplicity on record
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mútua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>September 8, 2015</study_first_submitted>
  <study_first_submitted_qc>September 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2015</study_first_posted>
  <last_update_submitted>January 31, 2019</last_update_submitted>
  <last_update_submitted_qc>January 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Corporacion Parc Tauli</investigator_affiliation>
    <investigator_full_name>Mireia Miquel-Planas</investigator_full_name>
    <investigator_title>phD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

